Recombinant factor VIIa: a general hemostatic agent? Yes
نویسندگان
چکیده
منابع مشابه
Challenges in the therapeutic use of a "so-called" universal hemostatic agent: recombinant factor VIIa.
Recombinant factor VIIa (rFVIIa) was developed in the early 1990s to provide "bypassing" hemostatic therapy for hemophilia A and B patients with inhibitors. More recently, it has been licensed for use in patients with inherited deficiency of factor VII. Since it was licensed for use in hemophilia with inhibitors in the US, Europe, and other countries for these specific indications, it has been ...
متن کاملRecombinant Factor VIIa: Hemostatic Adjunct in the Coagulopathic Burn Patient
INTRODUCTION Recombinant factor VIIa (rFVIIa; NovoSeven) is well recognized as an effective hemostatic agent in the management and prophylaxis of patients with hemophilia. We report here the successful use of rFVIIa in a coagulopathic burn patient. METHODS A 63-year-old man was admitted with significant upper-body burns in a total body surface area of 60%. Initial management included early in...
متن کاملEarly hemostatic therapy using recombinant factor VIIa in a collagenase-induced intracerebral hemorrhage model in rats.
Neurological deterioration during the first day after intracerebral hemorrhage (ICH) is associated with early hematoma growth in 18 to 38% of patients. While clinical studies continue to evaluate efficacy of activated recombinant factor VII (rFVlla) for reducing frequency of early hematoma growth, there have been no studies investigating the effect of rFVIIa on early hematoma growth. We used a ...
متن کاملHemostatic treatment in the early stage of intracerebral hemorrhage: the recombinant factor VIIa experience.
The treatment of intracerebral hemorrhage (ICH) has been a largely neglected item. In contrast to literally dozens of clinical trials of treatment of ischemic stroke, only a handful have addressed treatment of ICH with either medical (steroids,1 osmotic diuretics2) or surgical3 interventions. The medical intervention trials, primarily aimed at reducing brain edema surrounding the ICH, have show...
متن کاملUse of Recombinant factor VIIa in Obstetrics
6 The objective of this review article was to evaluate the current literature on the increasing off-label use of rFVIIa in the management of critical obstetric hemorrhage. Given the lack of high-level evidence, there is a need to review the clinical indications, observed response and adverse events. This review is designed to aid practitioners in deciding when and how to administer rFVIIa; It m...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thrombosis and Haemostasis
سال: 2004
ISSN: 1538-7933,1538-7836
DOI: 10.1111/j.1538-7836.2004.00909.x